Literature DB >> 16928883

Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Shamim H Kazmi1, Julian R Naglik, Simon P Sweet, Robert W Evans, Siobhan O'Shea, Jangu E Banatvala, Stephen J Challacombe.   

Abstract

Several human mucosal fluids are known to possess an innate ability to inhibit human immunodeficiency virus type 1 (HIV-1) infection and replication in vitro. This study compared the HIV-1 inhibitory activities of several mucosal fluids, whole, submandibular/sublingual (sm/sl), and parotid saliva, breast milk, colostrum, seminal plasma, and cervicovaginal secretions, from HIV-1-seronegative donors by using a 3-day microtiter infection assay. A wide range of HIV-1 inhibitory activity was exhibited in all mucosal fluids tested, with some donors exhibiting high levels of activity while others showed significantly lower levels. Colostrum, whole milk, and whole saliva possessed the highest levels of anti-HIV-1 activity, seminal fluid, cervicovaginal secretions, and sm/sl exhibited moderate levels, and parotid saliva consistently demonstrated the lowest levels of HIV-1 inhibition. Fast protein liquid chromatography gel filtration studies revealed the presence of at least three distinct peaks of inhibitory activity against HIV-1 in saliva and breast milk. Incubation of unfractionated and fractionated whole saliva with antibodies raised against human lactoferrin (hLf), secretory leukocyte protease inhibitor (SLPI), and, to a lesser extent, MG2 (high-molecular-weight mucinous glycoprotein) reduced the HIV-1 inhibitory activity significantly. The results suggest that hLf and SLPI are two key components responsible for HIV-1 inhibitory activity in different mucosal secretions. The variation in HIV inhibitory activity between the fluids and between individuals suggests that there may be major differences in susceptibility to HIV infection depending both on the individual and on the mucosal fluid involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928883      PMCID: PMC1595323          DOI: 10.1128/CDLI.00426-05

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  63 in total

1.  Parotid salivary basic proline-rich proteins inhibit HIV-I infectivity.

Authors:  M R Robinovitch; R L Ashley; J M Iversen; E M Vigoren; F G Oppenheim; M Lamkin
Journal:  Oral Dis       Date:  2001-03       Impact factor: 3.511

2.  Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.

Authors:  K Konopka; N Shine; E Pretzer; N Düzgüneş
Journal:  J Dent Res       Date:  1999-12       Impact factor: 6.116

3.  A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection.

Authors:  M Moriuchi; H Moriuchi
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

Review 4.  Breast milk transmission of HIV-1. Laboratory and clinical studies.

Authors:  P Van de Perre
Journal:  Ann N Y Acad Sci       Date:  2000-11       Impact factor: 5.691

5.  Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.

Authors:  H Hocini; P Becquart; H Bouhlal; H Adle-Biassette; M D Kazatchkine; L Bélec
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

6.  Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections.

Authors:  D L Draper; D V Landers; M A Krohn; S L Hillier; H C Wiesenfeld; R P Heine
Journal:  Am J Obstet Gynecol       Date:  2000-11       Impact factor: 8.661

7.  Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva.

Authors:  D C Shugars; L L Patton; S A Freel; L R Gray; R T Vollmer; J J Eron; S A Fiscus
Journal:  J Dent Res       Date:  2001-02       Impact factor: 6.116

8.  Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission.

Authors:  K Pillay; A Coutsoudis; A K Agadzi-Naqvi; L Kuhn; H M Coovadia; E N Janoff
Journal:  J Infect Dis       Date:  2001-01-18       Impact factor: 5.226

9.  Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva.

Authors:  D C Shugars; G D Slade; L L Patton; S A Fiscus
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2000-04

10.  Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.

Authors:  P Skott; E Lucht; M Ehnlund; E Björling
Journal:  Oral Dis       Date:  2002-05       Impact factor: 3.511

View more
  40 in total

Review 1.  Plausibility of HIV-1 Infection of Oral Mucosal Epithelial Cells.

Authors:  M C Herzberg; A Vacharaksa; K H Gebhard; R A Giacaman; K F Ross
Journal:  Adv Dent Res       Date:  2011-04

Review 2.  Mucosal transmission of human immunodeficiency virus.

Authors:  Denis M Tebit; Nicaise Ndembi; Aaron Weinberg; Miguel E Quiñones-Mateu
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

3.  Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity.

Authors:  Angela Wahl; Caroline Baker; Rae Ann Spagnuolo; Lisa W Stamper; Genevieve G Fouda; Sallie R Permar; Katie Hinde; Louise Kuhn; Lars Bode; Grace M Aldrovandi; J Victor Garcia
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

4.  Innate immunity including epithelial and nonspecific host factors: workshop 1B.

Authors:  A Weinberg; J R Naglik; A Kohli; S M Tugizov; P L Fidel; Y Liu; M Herzberg
Journal:  Adv Dent Res       Date:  2011-04

5.  MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.

Authors:  Louise A Ouattara; Patrick Barnable; Paul Mawson; Samantha Seidor; Thomas M Zydowsky; Larisa Kizima; Aixa Rodriguez; José A Fernández-Romero; Michael L Cooney; Kevin D Roberts; Agegnehu Gettie; James Blanchard; Melissa Robbiani; Natalia Teleshova
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins.

Authors:  Mary Requena; Hicham Bouhlal; Nadine Nasreddine; Hela Saidi; Jean-Chrysostome Gody; Sylvie Aubry; Gérard Grésenguet; Michel D Kazatchkine; Rafick-Pierre Sekaly; Laurent Bélec; Hakim Hocini
Journal:  Immunology       Date:  2007-11-10       Impact factor: 7.397

Review 7.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

Review 8.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 9.  Animal models of mucosal Candida infection.

Authors:  Julian R Naglik; Paul L Fidel; Frank C Odds
Journal:  FEMS Microbiol Lett       Date:  2008-04-16       Impact factor: 2.742

10.  Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN.

Authors:  Juan Sabatté; Ana Ceballos; Silvina Raiden; Mónica Vermeulen; Karen Nahmod; Julián Maggini; Gabriela Salamone; Horacio Salomón; Sebastian Amigorena; Jorge Geffner
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.